| Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
| 2018-11-10 |
Abbvie (USA - IL) Sandoz (Switzerland) |
- intellectual property relating to Humira®
|
plaque psoriasis, rheumatoid arthritis, axial spondyloarthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, polyarticular juvenile idiopathic arthritis, active enthesitis-related arthritis, hidradenitis suppurativa, non-infectious uveitis |
licensing
- biosimilar/monoclonal antibody/TNF alpha inhibitor. Adalimumab is a monoclonal antibody that binds specifically to TNF alpha and blocks its interaction with cell surface TNF receptors. It is used to treat many conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis and plaque psoriasis.
|
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Digestive diseases - Dermatological diseases |
Licensing agreement |
| 2018-10-18 |
Abbvie (USA - IL) Fresenius Kabi (Germany) |
MSB11022 - biosimilar version of Humira® (adalimumab) |
|
licensing |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Dermatological diseases |
Licensing agreement |
| 2018-10-16 |
Biomarin Pharmaceutical (USA - CA) Medivation (USA - CA), now Pfizer (USA - NY) |
talazoparib (BMN 673) |
metastatic breast cancer. |
product acquisition |
Cancer - Oncology |
Milestone |
| 2018-10-16 |
Ziopharm Oncology (USA - MA) |
member of the board of directors |
|
nomination |
Cancer - Oncology |
Nomination |
| 2018-10-15 |
Medivir (Sweden) |
|
|
nomination - restructuration |
Infectious diseases |
Restructuring |
| 2018-10-15 |
Sarepta Therapeutics (USA - MA) Lysogene (France) |
LYS-SAF302 |
mucopolysaccharidosis type IIIA (Sanfilippo B syndrome) |
licensing |
Rare diseases - Genetic diseases |
Licensing agreement |
| 2018-10-10 |
Ionis Pharmaceuticals (USA - CA) Roche (Switzerland) |
IONIS-FB-LRx |
complement-mediated diseases including geographic atrophy |
development |
Ophtalmological diseases |
Development agreement |
| 2018-10-09 |
Ziopharm Oncology (USA - MA) Precigen (USA - MD) |
Sleeping Beauty |
|
licensing |
Cancer - Oncology |
Licensing agreement |
| 2018-10-09 |
Iris Pharma (France) Keen Eye (France) |
artificial intelligence (AI) applications for bioimaging analysis |
ophtalmological diseases |
collaboration |
Ophtalmological diseases - Technology - Services |
Collaboration agreement |
| 2018-10-09 |
ERS Genomics (Ireland) GenAhead Bio (Japan) |
CRISPR/Cas9 genome editing technology patents |
|
licensing |
Technology - Services |
Licensing agreement |
| 2018-10-08 |
Sarepta Therapeutics (USA - MA) Paragon Bioservices (USA - MD) |
manufacturing platform for gene therapy programs |
|
manufacturing - bioproduction |
Rare diseases - Genetic diseases - Technology - Services |
Production agreement |
| 2018-10-08 |
eTheRNA immunotherapies (Belgium) |
mRNA manufacturing facility |
|
opening of new premises |
Cancer - Oncology - Technology - Services |
Opening of new premises |
| 2018-10-08 |
Vivebiotech (Spain) undisclosed European hospitals - undisclosed Norwegian company |
lentivirus |
cancers, undisclosed rare disease |
services contract |
Technology - Services |
Services contract |
| 2018-10-05 |
Sarepta Therapeutics (USA - MA) Nationwide Children’s Hospital (USA - OH) |
AAV1 neurotrophin 3 (NT-3) gene therapy |
Charcot-Marie-Tooth (CMT) neuropathies including CMT type 1A |
licensing |
Rare diseases - Genetic diseases - Neuromuscular diseases |
Licensing agreement |
| 2018-10-04 |
Arrowhead Pharmaceuticals (USA - CA) Janssen Pharmaceutical, a J&J Company (USA) |
- ARO-HBV and up to three additional RNA interference (RNAi) therapeutics
|
hepatitis B |
licensing - research |
Infectious diseases |
Licensing agreement |
| 2018-10-03 |
Boston Pharmaceuticals (USA - MA) Novartis (Switzerland) |
LYS228, IID572, MAK181 |
carbapenem-resistant enterobacteriaceae (CRE) infections, Pseudomonas infections |
licensing |
Infectious diseases |
Licensing agreement |
| 2018-10-03 |
Boston Pharmaceuticals (USA - MA) GSK (UK) |
GSK3352589, GSK3008356, GSK3183475 and two undisclosed preclinical programs |
acne, irritable bowel syndrome with diarrhea (IBS-D) |
licensing |
Autoimmune diseases - Dermatological diseases - Digestive Diseases - Inflammatory diseases |
Licensing agreement |
| 2018-10-03 |
Trovagene (USA - CA) Massachusetts Institute of Technology (MIT) (USA - MA) |
combination therapies that include anti-androgen or androgen antagonist and a Polo-like Kinase (PLK) inhibitor |
|
licensing |
Cancer - Oncology |
Licensing agreement |
| 2018-10-03 |
Cellular Biomedicine Group (China) National Cancer Institute (USA) |
next generation neoantigen-reactive tumor infiltrating lymphocyte (“TIL”) technology |
|
licensing |
Cancer - Oncology |
Licensing agreement |
| 2018-10-02 |
Kite Pharma (USA - CA), a Gilead company (USA - CA) HiFiBiO Therapeutics (USA - MA) |
neoantigen-reactive T cell receptors (TCRs) for the treatment of various cancers |
|
research - licensing |
Cancer - Oncology |
Licensing agreement |
